

FOIA MARKER

This is not a textual record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

Collection/Record Group: Clinton Presidential Records

Subgroup/Office of Origin: National AIDS Policy Office

Series/Staff Member:

Subseries:

OA/ID Number: 21067

FolderID:

Folder Title:

Angie Hendrickson [1]

Stack:

S

Row:

66

Section:

7

Shelf:

11

Position:

3

Withdrawal/Redaction Sheet

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. letter	re: Personal finances (1 page)	06/30/1998	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office

OA/Box Number: 21067

FOLDER TITLE:

Angie Hendrickson [1]

2018-0764-F

jm2213

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]


call → Sandy's
out of the country

done

ATTN: CHERYL FOR: MS. THURMAN 6/8/2000
FROM: ANGIE HENDRICKSON - WISCONSIN
715-256-9748 VOICE & FAX
angieric@execpc.com
715-281-0100 CELL

DEAR MS. THURMAN,
I JUST GOT CONFIRMATION OF
OUR NEXT NIH VISIT TODAY, AND AM
FORWARDING THAT INFO AS YOU
REQUESTED IN OUR CONVERSATION
LAST MONTH. IT WILL BE JUST
BRANNON AND MYSELF AS RICK FEELS
THAT I CAN SAY WHAT NEEDS SAYING.
SHOULD WE FIND TIME TO MEET, UNLESS
YOU WOULD LIKE HIM ALONG...
ARRIVE: 12:15 MIDWEST EXPRESS 6/19
FREE ALL AFTERNOON & EVENING
NIH: ROUTINE LABS/EXAM 6/20 A.M. APPT.
DEPART: 7:00 MIDWEST EXPRESS 6/20
WE SHOULD HAVE SEVERAL HOURS
OPEN BETWEEN NIH & DEPARTURE.
I AM ALSO ABLE TO EXTEND OUR
STAY FOR ANOTHER DAY, IF NEEDED.
THANKS AGAIN FOR YOUR CONSIDERATION.
RESPECTFULLY,
-ANGIE HENDRICKSON


Pregnancy Information Center
P.O. Box 554
Waupaca, WI 54981



FYI FROM:

Angie Hendrickson
N3723 N. Military Rd.
Weyauwega, WI 54983

THIS WENT GREAT!!
↓



In-Service Training
Tuesday, May 30
7:00 - 9:00 p.m.

"Ask the Expert"
With Dr. Catherine Martin and
AIDs Educator Angie Hendrickson

Bring along your questions on pregnancy, pre-natal care, fetal development, labor and delivery, contraceptives, post-abortion stress, AIDs and other Sexually Transmitted Diseases.

The PIC Clarion

Staff Newsletter 5/18/2000

PIC hires a "new" new Administrative Assistant

Apparently our announcement of Shari Manney becoming our new administrative assistant was a bit premature. As it turns out, Shari turned the job down. But don't despair. God always provides and He has proved Himself faithful in this situation as He has in so many others.

Just two days after we got Shari's call, God sent Patricia Dulske to us on (appropriately) the National Day of Prayer. She and a friend had been on their way to apply for a job at the public school administrative offices but weren't sure where they were located so decided to stop and join us at our prayer vigil first.

When I happened to mention that we were still looking for an administrative assistant, Patricia asked to fill out an application right then and there, was interviewed the following week, and hired just a few days after that.

Patricia is currently the treasurer for Fellowship Baptist Church here in Waupaca. She also works part time for a Bay Lakes Baptist Association headquartered in Manawa.

Patricia is the mother of 4 children whom she has

THIS IS A PRO-LIFE GROUP
AND IT WENT GREAT!
FOCUS ON PREVENTION
(ME) IF WE PREVENT,
ABORTIONS/UNWANTED
PREGNANCY WON'T BE
AN ISSUE. I KNOW
THERE WILL BE MORE
ASSESSMENTS/TESTING
HERE NOW...

Jane is an adoptive mom of 2. Please be praying for Jane as we know how difficult the enemy makes it for anyone interested in working at the Center. You can also be praying for two new recruits: Dana Krusa and John Paveleski. Say hello and offer an encouraging word if you happen to see them down at the Center.

"Ask an Expert" night slated for Tues., May 30 In-service

We've all had clients who have asked questions we could not answer. And there are many questions where we simply need to refer our clients to the experts for professional advice. However, all PIC volunteers can benefit from "asking an expert" about general topics of concern and that's just what you'll be able to do at our next Staff In-service meeting to be held Tuesday, May 30, starting at 7:00 p.m.

We are blessed to have at least two experts from the medical field who will answer your questions regarding basic pregnancy, fetal development, birth control and Sexually Transmitted Disease (STD) issues.

Our first "expert" is Dr. Catherine Martin, a family practitioner with Waupaca Family Medicine and Associates. Dr. Martin will share information and answers to such questions as:

- What physical symptoms require immediate referral to a physician for consultation?
- What can cause a "false negative" or "false positive" reading on a pregnancy test?
- How do oral contraceptives actually work?
- What is "the morning after pill" and how does it work?
- What is a "normal" menstrual period?
- Besides pregnancy, what are some other reasons that a woman might skip a period?
- What are some suggestions we can give clients to ease typical pregnancy symptoms such as nausea or back ache?

Our other "expert" is Angie Hendrickson, an AIDs educator here in the Waupaca area. Angie has a son whose been diagnosed with AIDs and has traveled the country sharing her story and information on AIDs and other STDs she garnered along the way. She'll address questions regarding:

- The transmission of HIV and other STDs.
- How do you minister to those who may have been exposed to or have contracted AIDs?
- Who is most at risk for getting such a disease?
- When should a person consider getting tested?
- How do you counsel clients regarding the risks of getting an STD?

We encourage you to write down any additional questions you might have for either one of these individuals and bring them along with you to the meeting. Please remember, though, that our experts can't comment on specific cases, although they will do their best to give you a better understanding of the subjects they're addressing.



NORTHWEST
AIRLINES

Department Number

Northwest Airlines, Inc.
5101 Northwest Drive
St. Paul MN 55111-3034

May 22, 2000

Brandon Lapinski
3723 N. Military Road
Weyauwega, WI 54983

Dear Brandon:

Just wanted to drop a note to thank you for the great job! The television commercial, "Portrait" turned out fantastic.

Enclosed is a video copy for your keeping. I hope you enjoy.

Be well, and thanks again.


Best Regards,

Craig Braasch
Managing Director of North America
Advertising and Sponsorships

cb/jb

ANOTHER FYI -
BRANDON IS IN
THIS SPOT WITH
PAUL MOLITOR OF THE
MINNESOTA TWINS
FOR CAMP HEARTLAND!
IT'S BEAUTIFULLY
DONE :)





Angie Hendrickson
HIV Prevention Education
Blood & Bio-Resource Consumer Advocate

Public Speaking:
References Available Upon Request

N3723 N. Military Road
Weyauwega, WI 54983
Voice & Fax (715) 256-9748



Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.

Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.

26 pgs




Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.

Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.

2 pgs





C.A.P.E.

COMMUNITY AIDS PREVENTION EDUCATION



Angie Hendrickson

8/15/2000

Dear Sandy, We have jumped off of the pier!
I sent in Articles of Incorporation today
and the name seems to be available at a
state level. The local support and affirmations
in regards to our efforts are positive and
profound!!! We have come full-circle here
at home... We hope to be a model that
others might use with cultural modifica-
tions, etc. as needed to meet their own
"epidemic"— Any and all help, support,
endorsements, sponsors, advice will be a
great gift. My heart is in the right
place and Rick is helping so much!
Thanks for listening to our story. Our
warmest regards and prayers —

P.S. Tell the Boss "HAPPY BIRTHDAY"

HE SHOULD COME JAM WITH THIS

BAND - THEY'RE REALLY GOOD CHICAGO BLUES!

PEACE & HEALTH

— ANGIE, RIC & BRANDON

N. 3723 N. Military Rd.
Weyauwega, WI 54983

angieric@execpc.com

Voice and Fax
715-256-9748

OVER →

P.S. I AM A FEATURED SPEAKER
AT WEIDNER CTR. FOR PERFORMING
ARTS - WORLD AIDS DAY EVENT
NOV. 26 - ARTISTS AGAINST AIDS
- ALSO: C.A.P.E. ALREADY REGISTERED
FOR AIDS WALK (WI) OCT 1. TEAM # 4018
- MEETING WITH ARC WAUPACA REGIONAL
DIRECTOR THIS THURSDAY - THEY ARE
LOOKING FOR SOMEONE TO TAKE
THE BALL AND RUN FOR THEM :)
- WORKING WITH NBC 26 NEWS
DIRECTOR, JOEL BERNELL ON ALL
OF THIS :)

PLEASE FORWARD THESE PHOTOS TO MRS.
GORE FOR ME. ~~IF~~ SHE HAS BEEN KIND AND I
ASKED FOR HER IN GREEN BAY. I WENT TO GIVE
HER MY BEST! SHE'S A NICE LADY :)

PLUS
MARK 
An American Greetings Company

100D 12472-3

© AGC, Inc.
MADE IN U.S.A.



CLINTON LIBRARY PHOTOCOPY

SEEMS LIKE NOBODY'S GONNA CALL FOR A CONTRIBUTION TO
ANY TIME CAPSULES SO I'M PRESENTING ONE FOR
CONSIDERATION. I AM SO TIRED... AS I SEE IT,
GOD IS GIVING ME A NEW START WITH THIS
MILLENNIUM!!! ONWARD AND UPWARD!!! ANYWAY,
ALL THE THINGS OF THE WORLD ASIDE  AS
HUMAN BEINGS TO

Wishing you every happiness throughout the holidays.

HUMAN BEINGS—
WHATEVER FAITH!!!

A VERY BLESSED HOLIDAY SEASON TO ALL...

OUR LOVE,
THE HENDRICKSON FAMILY



DECEMBER 20

*The world and its desire are passing
away, but those who do the will of God
live forever.*

1 JOHN 2:17

Everything around me seems stable and unmovable.
Release me from this illusion of permanence, Dear
God, and keep my will tied to your eternal will.

DECEMBER 24



*For to us a child is born; to us a son is
given; and the government shall be upon
his shoulder, and his name will be called
"Wonderful Counselor, Mighty God,
Everlasting Father, Prince of Peace."*

ISAIAH 9:6

As the pine tree is evergreen, it reminds us that
Your love is everlasting.

IT TAKES A VILLAGE...

CLINTON LIBRARY PHOTOCOPY



JANUARY 22

*I can do all things through him
who strengthens me.*

PHILIPPIANS 4:13

Christ, give me the strength to hang on during the
hard times, and the faith to know you'll be with me
until I come out on the other side.



JANUARY 26

*Faith is the assurance of things
hoped for, the conviction of
things not seen.*

HEBREWS 11:1

If we begin with certainties, we shall end in doubts;
but if we begin with doubts, and are patient in them,
we shall end in certainties.

—FRANCIS BACON



MAY 5

*You visit the earth and water it, you greatly
enrich it; the river of God is full of water;
you provide the people with grain,
for so you have prepared it.*

PSALM 65:9

Lord, when I look out my window today, let me see
your good hand at work in every growing thing.

SEPTEMBER 11

*But those who wait for the Lord shall renew
their strength, they shall mount up with wings like
eagles, they shall run and not be weary,
they shall walk and not faint.*

ISAIAH 40:31

I am still moving, God, through storms. By your
grace, you have carried me; amidst pounding waves,
you have held me; and beyond the horizon of my
longings, you have shown me your purpose.

JEREMIAH 3

9/10/99

¹⁵AND I WILL GIVE YOU LEADERS
AFTER YOUR OWN HEARTS, WHO
WILL GUIDE YOU WITH WISDOM
AND UNDERSTANDING.

²³WE ARE WEARY OF WORSHIPING
IDOLS ON THE HILLS AND OF
HAVING ORGIES IN THE MOUNTAINS.

ECCLESIASTES 1:18

...SO I WORKED HARD TO BE
WISE INSTEAD OF FOOLISH - BUT
NOW I REALIZE THIS WAS LIKE
CHASING THE WIND. FOR THE
MORE MY WISDOM, THE MORE
MY GRIEF; TO INCREASE
KNOWLEDGE ONLY INCREASES
DISTRESS.

" 3:16

MOREOVER, I NOTICE THAT
THROUGHOUT THE EARTH JUSTICE
IS GIVING WAY TO CRIME AND
EVEN THE POLICE COURTS ARE
CORRUPT. I SAID TO MYSELF, "IN
DUE SEASON GOD WILL JUDGE
EVERYTHING, MAN DOES, BOTH
GOOD AND BAD."

JEREMIAH 4:20²¹

WAVE UPON WAVE OF DESTRUCT-
ION ROLLS OVER THE LAND, UNTIL
IT LIES IN UTTER RUIN; SUDDENLY
IN A MOMENT, EVERY HOUSE
IS CRUSHED. HOW LONG MUST

Jeremiah:

THIS GO ON? HOW LONG MUST
I SEE WAR AND DEATH SUR-
ROUNDING ME?

"J" 31

I HAVE HEARD A GREAT CRYING
LIKE THAT OF A WOMAN GIVING
BIRTH TO HER FIRST CHILD; IT IS
THE CRY OF MY PEOPLE PLEADING
FOR HELP, PROSTATE BEFORE
THIER MURDERERS.

"J" 1:9/10

THEN HE TOUCHED MY MOUTH
AND SAID, "SEE, I HAVE PUT
MY WORDS IN YOUR MOUTH! TODAY,
YOUR WORK BEGINS, TO WARN
THE NATIONS AND THE KINGDOMS
OF THE WORLD. IN ACCORD
WITH MY WORD SPOKEN THROUGH
YOUR MOUTH I WILL TEAR
DOWN SOME AND DESTROY THEM,
AND PLANT OTHERS AND NURTURE
THEM AND MAKE THEM STRONG
AND GREAT."

"J" 1:17

GET UP AND DRESS AND GO OUT
AND TELL THEM WHATEVER I TELL
YOU TO SAY. DON'T BE AFRAID OF
THEM, OR ELSE I WILL MAKE A
FOOL OF YOU IN FRONT OF THEM.
FOR SEE, TODAY I HAVE MADE
YOU IMPERVIOUS TO THIER

ATTACKS. THEY CANNOT HARM YOU. YOU ARE STRONG LIKE A FORTIFIED CITY THAT CANNOT BE CAPTURED, LIKE A FORTIFIED CITY THAT CANNOT BE CAPTURED, LIKE AN IRON PILLAR AND HEAVY GATES OF BRASS.

JEREMIAH 14: 17/18

NIGHT AND DAY MY EYES SHALL OVERFLOW WITH TEARS. I CANNOT STOP MY CRYING, FOR MY PEOPLE HAVE BEEN RUN THROUGH WITH A SWORD AND LIE MORTALLY WOUNDED ON THE GROUND. IF I GO OUT IN THE FIELDS, THERE LIE THE BONES OF THOSE THE SWORDS HAVE KILLED; AND IF I WALK IN THE STREETS, THERE LIE THOSE DEAD FROM STARVATION AND DISEASE. AND YET THE PROPHETS AND THE PRIESTS HAVE MADE IT THEIR BUSINESS TO TRAVEL THROUGH THE WHOLE COUNTRY, REASSURING EVERYONE THAT ALL IS WELL, SPEAKING OF THINGS THEY KNOW NOTHING ABOUT.

" " 15: 19-21 GOD REPLIED:

"STOP THIS FOOLISHNESS AND
TALK SOME SENSE! ONLY IF YOU
RETURN TO TRUSTING ME WILL
I LET YOU CONTINUE AS MY
SPOKESPERSON. YOU ARE TO
INFLUENCE THEM, NOT LET
THEM INFLUENCE YOU! THEY
WILL FIGHT AGAINST YOU LIKE
A BESIEGING ARMY AGAINST
A HIGH CITY WALL. BUT THEY
WILL NOT CONQUER YOU FOR
I AM WITH YOU TO PROTECT
AND DELIVER YOU FROM THESE
WICKED MEN AND RESCUE YOU
FROM THEIR RUTHLESS HANDS.

PEACE & HEALTH
IN GOD'S OWN WORDS,
ANGIE


THE POST-CRESCENT

VIEWS

FRIDAY, SEPTEMBER 10, 1999 ■ B-5

providing news and leadership to Wisconsin's Fox River Valley since 1853


CLINTON LIBRARY PHOTOCOPY



F41 —

INDOOR
THUMBING!





Elusive prize: Oil rigs on the shore of the Caspian Sea in Baku, where the Minaret Group is based

A Z E R B A I J A N

Nice Truffles, But About Those Investment Tips ...

The 'Pirate of Prague' strikes again, and the losers this time include high-profile Americans

BY STEVE LEVINE AND
MARK HOSENBALL

VIKTOR KOZENY—A.K.A. "THE PIRATE of Prague"—sure knows how to mesmerize potential clients. Just before Christmas in 1997, Kozeny got Natalie Cole to serenade 150 wealthy Americans at a sit-down dinner in his \$20 million-dollar Aspen chalet. Gourmet chefs prepared the menu, which included a choice of nine entrees. Heaping bowls of sliced truffles were scattered around the house. The red Bordeaux was Château Mouton Rothschild; the dessert wine was the nectarlike Château d'Yquem. Everyone enjoyed over-the-top extravagance from a man whom many of them had never even met before. "It was the most lavish thing I've ever seen," one guest—who drives a Ferrari—told *NEWSWEEK*.

Some of the guests might now wish they'd never met Kozeny. At the bash and after, the 35-year-old Czech native with an Irish passport and a Harvard degree met with several new acquaintances and spoke to them about a potential fortune to be



Sour deal: Mitchell (right) invested with Kozeny (left), but the plan hasn't paid off

made in post-Soviet Azerbaijan. Now, nearly two years and \$450 million later, Kozeny's plan to take advantage of Azeri privatization schemes has turned sour. *NEWSWEEK* has learned that some investors, including Wall Street hedge-fund guru Leon Cooperman, have consulted lawyers and detectives to see if they can prove misrepresentation and perhaps recoup their presumed losses—by seizing Kozeny's Aspen chalet, for instance.

This is a cautionary tale about the new gilded age of global economics. Kozeny dangled the prospect of quick riches from "pri-

vatzation vouchers" offered by the Azerbaijan government—papers that could be bought cheap and used later to claim a piece of the country's prime assets as it privatized state industries. The best property that Kozeny indicated was up for grabs was Socar, the vast, state-owned oil company. For the record, several of Kozeny's investors say they haven't given up hope. But their vouchers expire next June, and so far the Azeris haven't offered to privatize any of the companies to which the Americans were attracted. Several American investors, including some who say they checked Kozeny out extensively before giving him their money, fear they've been duped.

Few of them are accustomed to losing. Out-of-luck investors include real estate magnate Richard Friedman, who owns the Martha's Vineyard estate where the Clintons

vacation, and former Senate majority leader George Mitchell. The senator even attended the gala opening of Kozeny's Minaret Group in Baku last year. Mitchell declined to comment on the matter to *NEWSWEEK*, but other attendees said Mitchell looked a tad embarrassed when none of Azerbaijan's senior leaders, on whom the Minaret venture relied, showed up.

Business people familiar with Kozeny's history aren't surprised. Kozeny earned his swashbuckling nickname in the Czech Republic during the early 1990s: he was fined for financial irregularities after earning \$200 million while many of his backers—including the 800,000 mostly small investors—were furious over their depleted investments. (Kozeny's controversial Czech windfall came from—you guessed it—privatization vouchers.) Kozeny gained further notoriety in 1997 after he spent \$21,000 on a business dinner with two colleagues in London's posh Mayfair district. (Kozeny complained that a \$9,000 bottle of La Romanée-Conti was "too young" and gave it to the kitchen staff.) In Baku, he established a similarly high profile, cruising the streets in an armored jeep with personal bodyguards and spending freely.

Kozeny himself denies wrongdoing. He told the London Sunday Times that he stands to lose more on the Azerbaijan investment than anyone. "They are all big boys," he said of his investors. "They knew it was going to be a risky endeavor from the start. I told them I was happy to take them along but I'm not going to be their psychiatrist as well." It's probably safe to say they're not going to ask him.

With NANA KIKNADZE in Baku

the pool size used by manufacturers of plasma-derived products. ..."

"FDA believes there should be upper limits set on plasma pool size for public health."

So now, at long last, FDA might issue a regulation on paid plasma pool sizes. Limits and actual enforcement is far into the future as the fractionators dig in their heels to save dollars.

Shays also rejected the fractionators' warning that smaller pools would have a negative impact on cost and supply, stating that safety was the primary goal.

Ed note: Background - The International Plasma Products Industry Association (IPPIA) has four members, Bayer, Baxter, Alpha (Green Cross) and Centeon (RPR and Hoescht). The president of IPPIA is Bob Reilly.

Bob Reilly is also the president of the American Blood Resources Association (ABRA) whose members are primarily the paid plasma collection companies which sell source plasma to the fractionators. Both organizations lobby at the State and Federal level.

The IPPIA is a relatively new trade organization, the fractionators wanted to distance themselves from the likes of Dr. Austin Stough and other unsavory types in the plasma collection business, so they created the exclusive IPPIA, for fractionators only.

Standard procedure for the fractionators, change the name, continue doing the same thing as before.

To contact Mr. Reilly with your opinion of paid plasma: Call or write to the IPPIA or ABRA, James Reilly (President), 107 Ridgely Ave., Suite 9A, Annapolis, MD, 21401, phone (410) 263-8296.

Make sure you tell him it is a IPPIA or ABRA question, it must get very confusing wearing two hats like Bob does.

David

. Postings: Hemophilia-Support@Web-Depot.COM
. Anonymous Postings: Anonymous-Hemophilia-Support@Web-Depot.COM
. Subscription Requests: Hemophilia-Support-Approval@Web-Depot.COM
. Questions: Owner-Hemophilia-Support@Web-Depot.COM
. World Wide Web: <http://www.web-depot.com/hemophilia>

. Hemophilia-Support is a free service provided by the Web-Depot, Inc.

Subj: Fractionators Caught in Lie to Congress
Date: 97-08-05 01:05:53 EDT
From: dgpowell@ix.netcom.com (David Powell)
Sender: sender-hemophilia-support@web-depot.com
Reply-to: Hemophilia-Support@web-depot.com
To: Hemophilia-Support@web-depot.com

After extensive investigation by the Shays subcommittee of the United States Congress, U.S. House of Representatives, the fractionators (Bayer, Baxter, Alpha, Centeon) have admitted to the Congress and the FDA that some current plasma pools can contain 400,000 donors.

Yes, up to 400,000 paid donors are used in plasma products sold today. Until a complete report is presented by the International Plasma Products Industry Association (IPPIA), the 400,000 paid donors in a completed product pool appears to be the industry high.

Bayer, market share leader in Factor products acknowledged that it was the company involved using paid donor pools of 400,000.

Last Thursday, during a hearing by U.S. Congressman Shay on blood safety, David Satcher, head of the CDC, made reference to this revelation in his prepared testimony. He told the subcommittee: "Typically, a single vial of a plasma-derived product, such as immunoglobulin or clotting factor, contains plasma from more than 10,000, and perhaps as many as 400,000 or more different donors."

In testimony later Thursday, Kathryn Zoon of the FDA acknowledged that "recent information indicates that the pool size, after adjusting for combination of intermediates, may result in the pooling of material from several hundred thousand donors for single lots of some products." (ed. note: Translated this means that a completed product is made of various components, maybe the Albumin is taken from this plasma pool, and the Factor protein is taken from another pool, and widget Z is taken from yet another plasma pool. Voila, risk to 400,000 paid plasma donors)

The industry did not readily volunteer this data. Earlier estimates obtained by FDA from the fractionators' trade group IPPIA indicated that the pools did not exceed 10,000 units of source plasma or 60,000 units of recovered plasma.

It appears that pressure from Congressman Shays (on industry and FDA alike) is the only reason the real numbers have finally been revealed.

It was unclear on Thursday whether indictments would be filed against the fractionators and the IPPIA for lying to Congress and the FDA.

Ms. Zoon of the FDA also shared this fact: THE FDA HAS NO REGULATIONS SETTING LIMITS ON POOL SIZE. But her testimony says it best so here it is:

"FDA has not established an upper limit to the size of plasma pools for the manufacture of plasma-derived products. FDA regulations are silent on pool size requirements except to specify the minimum pool size for the manufacture of immune globulin (human), a product used to treat hepatitis A. Therefore, FDA has limited information concerning

THE NAME "FRIEDMAN"
IS CERTAINLY SHOWING
UP OFTEN IN MY
DOCUMENTS —

BANK, BLOOD ...

FDA

MINARET GROUP


BAKU
AZERBAIJAN !!

~~DELTA FORCE~~

EXECUTIVE FOCUS

► Do you
have
what it
takes?

CIA
Directorate of Operations
Clandestine Service



► **THE ULTIMATE INTERNATIONAL CAREER**

For the extraordinary individual who wants more than just a job, this is a unique career — a way of life that will challenge the deepest resources of your intelligence, self-reliance, and responsibility. It demands an adventurous spirit, a forceful personality, superior intellectual ability, toughness of mind, and a high degree of personal integrity, courage, and love of country. You will need to deal with fast-moving, ambiguous, and unstructured situations that will test your resourcefulness to the utmost.

This is the Clandestine Service of the CIA. We are the cutting edge of American intelligence, an elite corps providing the vital information needed by our policy makers to address the national security interests of the American people. We face new challenges every day, in a world filled with increasingly complex issues. Ours is a mission like no other.

EMPLOYMENT OPPORTUNITIES

We are currently hiring officers for the Clandestine Service Trainee Program to serve internationally in two career tracks. Operations Officers spearhead our intelligence collection efforts and are actively involved in seeking new sources of information. Collection Management Officers coordinate our intelligence collection efforts and disseminate the product to U.S. government consumers.

The Clandestine Service has a second program, the Professional Trainee Program, for recent college graduates. Upon successful completion of this program, a Professional Trainee will be considered for the Clandestine Service Trainee Program.

The Clandestine Service Trainee Program is only one of several opportunities with the CIA. Maximum age for entry into the Clandestine Service Trainee Program is 35. U.S. citizenship is required. Both positions also require a minimum of a bachelor's degree with an excellent academic record. Outstanding interpersonal skills, the ability to write clearly and accurately, and a strong interest in foreign affairs are also necessities. A graduate degree — with specific study in physical, chemical, or biological sciences, international business or law, telecommunications, or computer technology — international residency, foreign language skills, and military experience are given strong emphasis in selecting competitive candidates. All selected applicants must successfully complete a thorough medical and psychological evaluation, a polygraph examination, and an extensive background investigation.

The CIA is an equal opportunity employer and a drug-free work force. We represent America and we want to be representative of America.

To apply for the Directorate of Operations, forward your resume and a cover letter, including your college GPA, to: CST Division, PO Box 12002, Dept. RAEC0399, Arlington, VA 22209; or FAX to CST Division: (703) 613-7871.

Competitive candidates for the Directorate of Operations will be contacted within 45 days.

If interested in U.S.-based positions in the fields of Computer Science and Engineering with the CIA, send your resume via FAX to (703) 613-7884, ATTN: DS&T.




**Challenges For
A Changing World**

Please visit our Web site at www.cia.gov

► Do you have what it takes?

CIA
Directorate of Operations
Clandestine Service



► THE ULTIMATE INTERNATIONAL CAREER

For the extraordinary individual who wants more than just a job, this is a unique career — a way of life that will challenge the deepest resources of your intelligence, self-reliance, and responsibility. It demands an adventurous spirit, a forceful personality, superior intellectual ability, toughness of mind, and a high degree of personal integrity, courage, and love of country. You will need to deal with fast-moving, ambiguous, and unstructured situations that will test your resourcefulness to the utmost.

This is the Clandestine Service of the CIA. We are the cutting edge of American intelligence, an elite corps providing the vital information needed by our policy makers to address the national security interests of the American people. We face new challenges every day, in a world filled with increasingly complex issues. Ours is a mission like no other.

EMPLOYMENT OPPORTUNITIES

We are currently hiring officers for the Clandestine Service Trainee Program to serve internationally in two career tracks. Operations Officers spearhead our intelligence collection efforts and are actively involved in seeking new sources of information. Collection Management Officers coordinate our intelligence collection efforts and disseminate the product to U.S. government consumers.

The Clandestine Service has a second program, the Professional Trainee Program, for recent college graduates. Upon successful completion of this program, a Professional Trainee will be considered for the Clandestine Service Trainee Program.

The Clandestine Service Trainee Program is only one of several opportunities with the CIA. Maximum age for entry into the Clandestine Service Trainee Program is 35. U.S. citizenship is required. Both positions also require a minimum of a bachelor's degree with an excellent academic record. Outstanding interpersonal skills, the ability to write clearly and accurately, and a strong interest in foreign affairs are also necessities. A graduate degree — with specific study in physical, chemical, or biological sciences, international business or law, telecommunications, or computer technology — international residency, foreign language skills, and military experience are given strong emphasis in selecting competitive candidates. All selected applicants must successfully complete a thorough medical and psychological evaluation, a polygraph examination, and an extensive background investigation.

The CIA is an equal opportunity employer and a drug-free work force. We represent America and we want to be representative of America.

To apply for the Directorate of Operations, forward your resume and a cover letter, including your college GPA, to: CST Division, PO Box 12002, Dept. RAEC0399, Arlington, VA 22209; or FAX to CST Division: (703) 613-7871.

Competitive candidates for the Directorate of Operations will be contacted within 45 days.

If interested in U.S.-based positions in the fields of Computer Science and Engineering with the CIA, send your resume via FAX to (703) 613-7884, ATTN: DS&T.



**Challenges For
A Changing World**

Please visit our Web site at www.cia.gov



AP file photo

Children watch a U.S. plane bring supplies during the 1948 West Berlin blockade. The Soviet blockade is viewed by historians as the onset of the Cold War.

Veil lifted on deadly Cold War spying

CIA declassifies files on Berlin operations

By John Diamond

TRIBUNE STAFF WRITER

BERLIN—The smudged carbon dispatches from former West Berlin lack the style of a LeCarre novel but not the terror.

Amid a bureaucratic drone that belies their "top secret" markings, the vivid passages from the late 1940s and early 1950s, the peak of the U.S.-Soviet spy wars in Germany's divided city,

emerge all the more vividly.

In one dispatch from 1948, a senior U.S. intelligence operative in Germany laments the speed and ruthless efficiency with which Soviet and East German security forces rolled up networks of pro-Western spies.

"As we learned to our cost, the time margin was extremely small," between the Soviets learning of a ring and closing in. "Once the trap was sprung, it was usually too late for us to rescue the more remote agents," the senior operative reported.

"We have since learned something of the cost to the agents themselves:

sentences of 5 to 25 years in Siberia, misery and even destitution among the families left behind."

The "eyes only" memo is one of hundreds of newly declassified documents compiled by the CIA on the history of spy operations in Berlin, a

SEE SPIES, BACK PAGE



FROM PAGE ONE

CIA documents reveal deadly intrigues

With the onset of the Cold War in the 1940s, the U.S. and Western allies feverishly worked to employ spies against the Soviets and East Germans. Many of those spies were quickly and ruthlessly rounded up.

CONTINUED FROM PAGE 1

key battleground of Cold War espionage.


Release of the documents, in a volume titled "On the Front Lines of the Cold War," is intended to coincide with the anniversary of the Nov. 9, 1989, fall of the Berlin Wall. The CIA is marking the occasion with a conference in Berlin this weekend on the spy wars of the 1940s and '50s that contributed to the wall's rise.

Some of the veterans—at least those who survived the sprung traps—will be on hand to reminisce.

The same 1948 memo coldly notes that U.S. intelligence operatives learned a great deal about Soviet counter-espionage techniques by watching the roundup operations unfold. Often the first indication that the Soviets were aware of an espionage cell were that one or more members would be kidnapped while others would be approached in the hope they could be "doubled" or turned back to work against the West.

Even when the CIA reacted in time and shut down a spy cell before the Soviets moved in, little could be done to protect the actual field operatives.

"Many of our casualties were agents whom we had dropped many months before they were captured, and they in turn implicated other dropped agents and some who were still active," the 1948 memo states.



AP file photo

The ruthlessness of the spy wars is suggested by biographical material the CIA developed on senior Eastern Bloc intelligence officials. One of them, Gen. Ivan Serov, had been responsible during the Soviet occupation of the Baltic states early in World War II for the deportation of 134,000 "class enemies" to slave labor camps.

A CIA source described Serov as restrained when he overruled a subordinate who immediately wanted to execute a suspected spy. The source quoted Serov as saying that the suspect should be made to talk, thereby being much more useful in the counter-espionage investigation than if he were dead.

The documents describe the initial advantage the Soviets had in recruiting spies but also recount how a Soviet general, drunk on four glasses of vodka and five of whiskey, regaled a CIA agent with insider gossip on the Politburo.

The CIA's intelligence report at times revealed the Soviets to be somewhat less efficient and controlling than was believed at the height of the Cold War.

One secret dispatch from Berlin to CIA headquarters describes an informant's report on a conference between Soviet and East German officials just as Moscow was launching the 1948 Berlin blockade. The East Germans, it turns out, were upset that the blockade would shut off the flow of raw materials and finished supplies essential to keep industries in the eastern sector running.

The Soviets had neglected to consider this possibility.

"The Russians appeared greatly shocked and a Russian general in charge of trade and supply said, 'We had no idea of the situation ... If we had known this, we would not have gone so far,'" according to the CIA field report.

The CIA had its own troubles, even when it seemed to have everything going its way, as in the case of Oleg Penkovsky, a CIA

mole inside Soviet military intelligence. In one 1961 debriefing contained in the newly released collection, Penkovsky said he had four days' advance warning of the construction of the Berlin Wall but could not relay the information because his CIA handlers had limited him to a few regularly scheduled contacts.

"I wanted to pass this information to you but had no means for doing this, since the phone call arrangement was only good for Mondays ...," Penkovsky said.

The declassified documents also detail the CIA's construction of a tunnel into East Berlin to tap Soviet military phone lines—and how the Soviets knew about it before the tunnel was even built—and show how the building of the Berlin Wall cut off the CIA from its hard-won sources in the East.


As the Cold War fades into history, it becomes increasingly difficult to recall the level of tension between the Soviet Bloc and the West. Much of that tension was focused on Berlin, where, in the view of many historians, the Cold War truly began with the 1948 Soviet blockade of the city.

The western half of the city, controlled jointly by the United States, Britain and France from the end of World War II, was an island of Western sovereignty surrounded by Soviet-dominated East Germany. West Berlin represented the most tempting place for Moscow to test the U.S. and Allied resolve to defend against communist expansion. For the West, the city offered the best observation post to peer behind the Iron Curtain.

It also is easy to forget that the Berlin Wall itself, that most tangible symbol of the Cold War, was a relative latecomer to the East-West conflict. The Soviet-backed East German government built the wall in a sudden move on the night of


The depths of the Cold War

In 1954, the CIA begins digging a 500-yard tunnel from the American sector of Berlin into the Soviet sector to use as a listening post. By tapping into phone lines, the U.S. hoped to obtain military intelligence. In 1956 the Soviets revealed they knew about the project and it was shut down.



Source: News reports

The Berlin tunnel



Chicago Tribune/Kevin Hand, Phil Geib and Mitchel May

Aug. 12-13, 1961, catching the CIA and other Western intelligence agencies by surprise.

The wall was a highly successful political coup for the Eastern bloc. It shut down the flow of refugees from the East who were draining the communist nation's labor supply. And it effectively sealed off East Berlin from Western intelligence agencies, closing down highly productive lines of otherwise unavailable information about Soviet plans and capabilities.

The documents released by the CIA end with the construction of the wall. After that, Berlin ceased to be the center of the East-West intelligence struggle. The battle shifted to places like Vietnam, Angola and Latin America.

Especially for the United States, the information-collecting effort also went into outer space, as spy satellites with cameras, heat-detecting devices and eavesdrop-

ping equipment converted the trickle of information on the Soviets coming from clandestine sources into a flood.

The CIA's ambitious foray into technical intelligence collection had its precursor in the Berlin tunnel operation. An audacious gambit that stemmed from the difficulty of recruiting willing sources in the heavily policed Eastern bloc, the 500-yard tunnel passed under the border between the two halves of Berlin to a point just under a telephone trunk line that included several Soviet and East German military circuits.

Human sources were able to provide the CIA with the layout of the underground phone cable, but it took a year to dig the tunnel, which was completed in early 1955.

In a top-secret memo written to CIA Director Allen Dulles, a senior agency official in Germany wrote during the planning phase

that "the key to the success of this project is primarily a matter of maintaining the highest possible degree of security."

But on Oct. 22, 1953, just a month after the memo was written, the CIA blew its own operation before a single shovel full of dirt had been turned.

That day, CIA officials briefed their British counterparts, who would help with the project. Present at the London meeting was George Blake, a KGB mole who duly alerted his KGB handler in London.

Only in 1961, when Blake was exposed as a spy and arrested would the CIA learn that its prized project had been compromised from the beginning. But the agency concluded that the reams of intelligence taped, translated and sorted by more than 300 analysts was genuine and not a KGB disinformation campaign.

Scores

CONTINUED FROM PAGE 1

How students did on the new ISAT

The first round of the new Illinois Standards Achievement Test was administered last February to 532,305 students in four grades.

ing, about 36 percent did not meet the standards in writing and about 43 percent did not meet the mathematics standards.

Last year 30 percent of young-

solve multiple-step "real life" story problems instead of calculating the answer to isolated problems.

For example, instead of figuring out the length of the hypotenuse

CLINTON LIBRARY PHOTOCOPY

A Nazi-Era Bill Finally Comes Due

Survivors of World War II's slave-labor camps are filing suits against the companies that profited from their work. The tab could be billions of dollars.

By MICHAEL HIRSH

WACLAW KOŁODZIEJ-
jek stands up, the smile frozen on his face, and pulls open his golf shirt. There on his chest, tattooed in bluish purple, are the numbers 2254. They are slightly askew and off-center, as if the German who injected them was in a hurry. And in August 1940, when Kolodziejek arrived at Auschwitz, the Nazis were very much in a rush. Anxious to build their extermination factory, they yanked Kolodziejek and thousands of other Poles off the streets of Warsaw as conscripted labor. Kolodziejek—a 17-year-old Catholic with movie-star looks—was on one of the first transports to Auschwitz. At the camp, he was beaten and terrorized. In 1942 Josef Mengele experimented on him, Kolodziejek says. Later he nearly starved. He laughs about it now—except when discussing Mengele, then his voice breaks—because there's nothing else he can do.

Kolodziejek spent the entire war in the camps. He worked for three horrific years at Auschwitz, eventually at a job carting rubber solvents for IG Farben, the German chemical giant. Later he constructed planes for Messerschmitt at Mauthausen, a slave-labor camp operated by the Nazis in Austria. His experience is a reminder of the strategy behind the thousand-year Reich's 12-year reign. Nazi Europe was run as a kind of pyramid scheme: conquer a country, then enslave its citizens to empower the machine to conquer more. Under fascism, the corporations that sustained this empire thrived on the low overhead provided by millions of slave laborers like Kolodziejek.

Until now, most of these companies escaped history's notice. Only three firms—Farben, Krupp and Flick—were prosecuted after the war, and a few more paid a pittance in compensation. But in recent months, inspired by last year's \$1.25 billion settlement between victims of the Holo-



Marquee names that escaped history's notice: Hitler inspects the first Volkswagen, 1936

caust and Swiss banks, lawyers have filed more than two dozen class-action lawsuits alleging that manufacturers, construction outfits, banks and insurance companies in Europe, Britain and the United States profited from the Holocaust. German companies, of course, have attracted most of the legal attention: marquee names like Daimler-Benz, Volkswagen, Siemens and dozens of others allegedly enslaved hundreds of thousands of Poles, Czechs, Russians and Ukrainians to build camps and armaments and to work in plants. Last week a top aide to German Chancellor Gerhard Schröder met with survivors groups and U.S. officials to try to fashion a universal settlement covering German companies. Lawyers

expect the settlement to exceed \$10 billion.

Germany, however, is not the only legal target. In Australia, former POWs and civil internees are pressing actions against the Japanese over their own enslavement. U.S. lawyers are discussing another suit with Moscow on behalf of Russian slave laborers, *NEWSWEEK* has learned. In addition, half a dozen U.S. companies with German subsidiaries that operated during the war, including GM and Ford, are being investigated by lawyers such as Washington attorney Michael Hausfeld, one of several who filed the Polish suit.

All this is a lesson in how the 20th century's darkest horror haunts the 21st century's greatest goal: global integration. As



Title: CONVENTION ON THE PROHIBITION OF THE DEVELOPMENT, PRODUCTION AND STOCKPILING OF BACTERIOLOGICAL (BIOLOGICAL) AND TOXIN WEAPONS AND ON THEIR DESTRUCTION (1972)

Filename: bio-wep.htm

Table of contents

- Title: CONVENTION ON THE PROHIBITION OF THE DEVELOPMENT, PRODUCTION AND STOCKPILING OF BACTERIOLOGICAL (BIOLOGICAL) AND TOXIN WEAPONS AND ON THEIR DESTRUCTION (1972)
- Source:
- Dates:
- Text
- Preamble
- Article I
- Article II
- Article III
- Article IV
- Article V
- Preamble
- Article VI
- Article VII
- Article VIII
- Article IX
- Article X
- Article XI
- Article XII
- Article XIII
- Article XIV
- Article XV

Title: CONVENTION ON THE PROHIBITION OF THE DEVELOPMENT, PRODUCTION AND STOCKPILING OF BACTERIOLOGICAL (BIOLOGICAL) AND TOXIN WEAPONS AND ON THEIR DESTRUCTION (1972)

Title: CONVENTION ON THE PROHIBITION OF THE DEVELOPMENT, PRODUCTION AND STOCKPILING OF BACTERIOLOGICAL (BIOLOGICAL) AND TOXIN WEAPONS AND ON THEIR DESTRUCTION (1972)

Subj: Bayer Biological Warfare
Date: 97-08-31 00:27:49 EDT
From: dgpowell@ix.netcom.com (David Powel)
Sender: sender-hemophilia-support@web-depot.com
Reply-to: Hemophilia-Support@web-depot.com, dgpowell@ix.netcom.com (David Powel)
To: Hemophilia-Support@web-depot.com

D. Wiesner wrote:

"In June, 1991, the San Francisco Examiner published a story entitled, "Germ War Lab Alarms Berkeley" which noted the community of West Berkeley "was home to the Defense Department's one and only supplier of antiplague vaccine." On December 28, 1990, four maintenance men made an unauthorized entrance into a room at Cutter Biological which housed Yersinia pestis, commonly known as "The Black Plague," which once killed a quarter of the population of Europe 650 years ago.

I haven't seen this article, so I can't tell you if the description above is accurate. Watch out, Ken!"

These 1990-1991 newspaper articles are included in the Bay Area hemophilia archives. These are quite interesting articles published in Oakland and San Francisco, California newspapers.

Biological warfare development of bubonic plague, anthrax and other biological warfare weapons were developed by Bayer for the U.S. Defense Department.

The U.S. DOD contract for Bayer biological weapons research and experimental biological countermeasures (vaccines) were signed long ago, before Desert Storm.

David

.....
.. Postings: Hemophilia-Support@Web-Depot.COM
.. Anonymous Postings: Anonymous-Hemophilia-Support@Web-Depot.COM
.. Subscription Requests: Hemophilia-Support-Approval@Web-Depot.COM
.. Questions: Owner-Hemophilia-Support@Web-Depot.COM
.. World Wide Web: <http://www.web-depot.com/hemophilia>
..
.. Hemophilia-Support is a free service provided by the Web-Depot, Inc.
.....

----- Headers -----

Received: from mrin53.mail.aol.com (mrin53.mx.aol.com [198.81.19.163]) by air06.mx.aol.com vx with SMTP; Sun, 31 Aug

In fact, internal documents obtained by the Tribune show that the university knew about serious lapses in research methods long before federal regulators stepped in. An audit dated Dec. 10, 1998, found that "there is still a risk that research on human subjects could take place" without proper approval of the internal review board at UIC.

President James Stukel, who is Broski's boss and leads the entire three-campus University of Illinois system, had ordered the audit of the Chicago campus' research practices shortly after the federal government instituted a similar research suspension at Rush-Presbyterian-St. Luke's Medical Center.

Broski has said he assumed

SEE UIC, BACK PAGE



Tribune file photo

Days before his resignation, UIC Chancellor David Broski assumed responsibility for the school's human-research violations cited by U.S. regulators.

quits; may have been shoved out

Chancellor took blame for human research suspension at school

By Patrice M. Jones

TRIBUNE HIGHER EDUCATION WRITER

Chancellor David Broski of the University of Illinois at Chicago shocked students and staff Thursday when he tendered his resignation effective immediately, after enduring weeks of harsh criticism over the suspension of virtually all research on humans at the Near West Side campus.

In a move that is a steep departure from traditional university protocol, Broski will not stay on as chancellor during the transition to find a permanent replacement, even though the fall semester has just begun. He also announced no immediate career plans and declined to comment, fueling speculation that he was forced out as scrutiny over the university's research practices began to mount.

Susan Trebach, a spokeswoman for Stukel, said that following the audit, UIC's office of the vice chancellor for research made some recommended changes, but not enough to satisfy federal regulators.

The overall response to the internal audit was "seriously inadequate," she said.

When federal regulators suspended research on humans at UIC two weeks ago Friday, they said university researchers had failed to get sufficient informed consent from some research patients. Regulators also found deficiencies in a UIC office responsible for coordinating safety reviews.

Stukel has named Sylvia Manning, the systemwide vice president for academic affairs, to serve as interim chancellor. He said a national search would be conducted for Broski's replacement, which would take between six and eight months.

Broski's colleagues seemed startled over his departure.

"It is a very sad day for our campus," said UIC Provost Elizabeth Hoffman, who was hired by Broski. "He was a real visionary for this campus."

Broski was noted for everything from attracting more bright students to boosting UIC's profile in athletics. While Broski is out as chancellor, he is a tenured professor and could return to the classroom.

Even some personnel who have criticized the administration over the recent research suspension said Thursday that Broski's resignation does little to address the research problem.

Dr. Jeffrey Sosman, a UIC breast researcher, said Thursday that Broski's resignation leaves many questions unanswered about how the university allowed violations to go unaddressed for so long that regulators took action.

"I'm still wondering if we've gotten to the bottom of this," Sosman said. "Broski was not involved in the initial problems. Have we really clarified who is to blame?"

Marla Baker, one of 10 members of UIC's research review board to resign earlier this year in protest over alleged shortcomings in human protections, said she had not thought the research suspension would topple Broski.

"There's clearly been much more discussion about this behind closed doors than some of us ever imagined," she said.

Tribune staff writers Ray Long and Jeremy Manier contributed to this report.

X UIC

CONTINUED FROM PAGE 1

responsibility for violations cited by federal regulators.

Stukel would not confirm Thursday that Broski was forced out but said that he and Broski had a "far-reaching" conversation earlier that morning about the future of UIC. After the conversation, Broski resigned, Stukel said.

"We had a conversation about the university and the issues that have been in the papers in the past several months," Stukel said. "At the end of that conversation, he made a decision."

Broski, 53, a longtime health administrator at UIC who had risen with Stukel's influence, has been embroiled in one controversy after another during much of his three-year tenure as chancellor—from the university's controversial \$500 million South Campus expansion project to officials' bold move to merge with John Marshall Law School.

Moreover, Broski had presided over the hiring of several high-profile scholars who were taking the university in a new academic direction. Most notable was former Duke University English department chairman Stanley Fish, who as dean of the college of liberal arts and sciences recently hired University of Iowa economics professor Deirdre McCloskey as a visiting professor. McCloskey has undergone a sex-change operation and wrote a book about her transformation scheduled for extensive publicity in October.

As the series of high-profile controversies grew, the well-established support of Broski by his longtime mentor, Stukel, had begun to wane in the past year.

But the events of the past weeks appear to have quickly unraveled an already strained relationship. Less than two weeks ago, more than 600 faculty, students and staff members packed a town hall meeting on campus, posing pointed questions about why federal regulators had halted research at the school. They voiced concerns that the fallout from the suspension could damage everything from ongoing research at UIC, to applications for federal grants.

Broski said at the time that he was the one responsible for UIC's problems. But whether Stukel and others also will have to answer for the highly public reprimand of the university remains to be seen.

CLINTON LIBRARY PHOTOCOPY

miss' e abilit'es

ASSOCIATED PRESS

WASHINGTON—Over the next 15 years, North Korea and Iran are likely to develop missiles potentially capable of killing millions of Americans, the CIA said Thursday.

In an intelligence report with major implications for the Pentagon's efforts to develop defenses against ballistic missiles, the CIA said Iraq poses an additional—though somewhat more distant—threat. It said that it is questionable whether Iraq could test a missile with enough range to reach the United States before 2015, though the likelihood depends heavily on how much foreign assistance Iraq gets.

The report said North Korea could flight-test its first intercontinental-range ballistic missile "at any time," putting that communist nation in the category of a missile threat to the U.S. as early as this year. It is far from clear, however, whether a North Korean test launch would be successful. The CIA rated Iran's prospect of developing an ICBM by 2015 as "probable." Iraq was labeled a "possible" threat.

These emerging missile forces "potentially can kill tens of thousands, or even millions, of Americans," depending on their accuracy and whether they are armed with nuclear, chemical or biological warheads, it said.

The U.S. has no means of shooting down long-range ballistic missiles, although the Pentagon is spending billions of dollars to develop anti-missile missiles to shield the U.S. against a limited attack.

Russia already has about 1,000 long-range missiles with about 4,500 nuclear warheads. China has about 20 missiles capable of reaching the U.S..

The CIA report said that short-range ballistic missiles, such as Iran's Shahab-3 and North Korea's No Dong, pose an "immediate, serious and growing threat to U.S. forces, interests and allies" in the Middle East and Asia. Those missiles do not have the range to reach U.S. soil.

The report said that the countries developing ballistic missiles also probably are working on "counter-measures," or ways of enabling their missiles to overcome U.S. defenses. Russia and China, which already have developed numerous countermeasures, probably are willing to sell these technologies, it said.

The report is a summary of a classified National Intelligence Estimate, the first the CIA has done on ballistic missile threats since 1995. In an October 1998 update of its assessment, the CIA told Congress that the United States was facing a growing threat from the spread of ballistic missiles.

BIO-CHEMICAL AGENTS

LAGOS
in this c
Thursday,
ple were k
Police sa
linked to
missed ser
Maritime
Nigeria to
force, with
tant ethnic
Dockwor
workers a
was domin
from the
apparently
many fell
among tho
Nigeria's m
"The troi

EGYPT
Official
in Mub

CAIRO
gence chie
and given a
day, three
dent Hos
attacked a
by a knife
rior Minis

The off
Hani el-A
post of b
The movi
tions into
Mubarak
of Port S

The o
was rep
Lt. Gen.
gave no

Earlie
top po
Said w
plinary
dereli
Mubar

Drug blocks side effects of cancer treatment

By Jeremy Manier
TRIBUNE STAFF WRITER

In a finding that could help relieve the most devastating side effects of cancer treatment, Chicago researchers said Thursday they have developed a drug that might allow cancer patients to survive high doses of radiation or chemotherapy without suffering severe illness.

A team of scientists from the University of Illinois at Chicago and Rush-Presbyterian-St. Luke's Medical Center injected mice with a compound that keeps healthy cells from committing suicide once damaged by gamma-ray radiation. Their results raise the possibility that similar treatments could reduce damage from many kinds of trauma, including stroke and heart attacks.

"This is definitely the first step, but it looks promising," said Andrei Gudkov, a UIC molecular geneticist who led the team. The results are published in Friday's edition of the journal *Science*.

Although the technique has been tried only in mice and applications in humans are years away, cancer experts said it represents a novel approach that should spur additional lines of research.

If it works in humans, the treatment could provide a new way of reducing the nausea, diarrhea, weight loss and immune system problems that often beset cancer



Tribune photo by Heather Ston

UIC's Andrei Gudkov, leader of the cancer side effects study, and colleagues Lena Komarova and Pavel Komarov hold mice in his lab.

patients on chemotherapy or radiation, doctors said.

The findings shed new light on how researchers might harness a mechanism called programmed cell death, which biologists have begun to understand only in the last decade. Also called apoptosis, the process is meant to ensure that cells with genetic damage destroy themselves before they can pass on their defects to subsequent generations of cells.

Sometimes, as in the case of radiation therapy for cancer, apoptosis kills healthy cells that

might recover if they had time. Gudkov's team discovered that a compound they called pifithrin alpha (PFTa) temporarily disables the gene responsible for apoptosis.

"I was very impressed by the creativity of this [study]," said Dr. Bert Vogelstein, a cancer researcher at Johns Hopkins University.

Vogelstein led a team that in 1989 discovered that p53, the apoptosis gene, is mutated or missing in many kinds of cancer tumors. That finding has led Vogelstein and others to focus on ways of reactivating p53 in tumors so they destroy themselves.

The UIC team's insight, Vogelstein said, was that interfering with p53 for a short time could protect healthy cells from being harmed by otherwise toxic therapies.

"What I thought was really fascinating and novel about their paper was the way it turns previous research on its head," Vogel-

Corrections and clarifications

■ In the review of the movie "Stigmata" in today's preprinted Friday section, the last sentence of the first paragraph should read: With our brains presumably soiled, we are seen as prime target for such claptrap

as "Stigmata."

■ In a story about an injury to Frank Thomas in Thursday's Sports section, the name of White Sox podiatrist Lowell Scott Weil was misspelled.

The Tribune regrets the errors.

therapy in mice, UIC

Preserving healthy cells during cancer treatment

Radiation or chemotherapy used for cancer treatment can damage healthy cells. Researchers may have found a way to protect healthy cells by interfering with the p53 gene, which causes healthy cells to self-destruct when exposed to chemotherapy or radiation. This genetic suicide can lead to nausea, weight loss and immune system problems.



Normal cell under attack




Damaged cell

How cells die

Damage to the cell from cancer therapy or other sources triggers p53 and a suicide process called apoptosis begins.

Enzymes are released that cause disintegration of the cell's DNA. This kills the cell.



Sources: The Journal of NIH Research, Ohio State University's James Cancer Hospital and the University of Illinois at Chicago and Rush Presbyterian St. Luke's Medical Center

Chicago Tribune / Jeremy Manier, Melissa Nagy, Rick Tuma and Lara Weber

Preventing cell death

Scientists have discovered a compound called pifithrin-alpha (PFTa) that temporarily stops the p53 gene from triggering the death of healthy cells.

Drawbacks of drug

Treatment with PFTa, however, might help healthy cells with some genetic damage survive and develop into tumors. This effect was not found in mice, but could pose a problem in humans.

perienced none of the weight loss that plagued irradiated mice that did not get the drug.

Gudkov said one important quality of PFTa and similar drugs is that they are quickly metabolized in the body, disappearing within a few hours after radiation treatment.

Disabling the cell suicide gene permanently would be disastrous because it could let truly defective cells survive and turn into cancer cells.

"By blocking p53 temporarily we allowed many healthy cells to survive," Gudkov said.

After seven months, his team found no tumors in mice treated with PFTa and radiation. Experts say that making sure the drug does not promote tumors in humans will be a major focus of future clinical trials.

The UIC and Rush research, being funded by Quark Biotech, Pleasanton, Calif., company. Gudkov said his group probably would complete animal tests within a few months, and preliminary safety trials in humans could start as early as next year pending a go-ahead by the Food and Drug Administration.

Preliminary results suggest treatment may also be effective in reducing side effects of chemotherapy, which often has more serious side effects than radiation because it is more difficult to target in one part of the body.

"What's really exciting is the idea that you could give a little more of a drug and kill more cancer cells," Vogelstein said.

Scientists also believe a major part of the damage from stroke, heart attack and burns happens when blood-starved cells commit suicide.

Gudkov said his team is in the early stages of testing PFTa for use with such injuries.

tein said. "It says maybe we could exploit this process in normal cells."

To find a substance that would block p53, Gudkov and colleagues screened 10,000 different compounds from a standard chemical library. A few, including PFTa, interfered with the suicide gene and appeared safe enough to be drug candidates.

The team worked with hundreds of mice to determine the effects of PFTa, giving the drug to some animals hours before subjecting them to intense radiation.

The results in such cases were dramatic. Gamma-rays powerful enough to kill 60 percent of mice under normal conditions did not kill a single mouse in the group taking PFTa. Such mice also expe-

SEE CHANCELLOR STORY

REMEMBER PAST
RECES I SENT DAVE?

M. FRIEDMAN

Medical researchers testing without asking

The most controversial aspect about trials involving an oxygen-carrying blood substitute was not the higher than expected death rate but the fact that consent was never obtained from the patients.

By Jeremy Manler
TRIBUNE STAFF WRITER

Two years ago, researchers for Deerfield-based Baxter International Inc. began the first advanced trial of an oxygen-carrying blood substitute with great hopes that the product might one day revolutionize emergency medicine by providing a ready treatment for people of all blood types.

That didn't happen. The trial was halted because out of 52 emergency trauma patients around the country who received the blood substitute

called HemAssist, 24 died—two more than would have been predicted given the severity of their injuries and far more than the death rate in a group that received only routine treatment.

Though the trial's disappointing results were widely reported last summer, the assessments did not examine its most controversial feature: Consent was never obtained from patients in the study. But recently, some medical experts have called for federal regulators to revisit the policy that permits some experiments on humans to be conducted without the consent of patients or their families.

The absence of consent was allowed under a historic 1996 change in U.S. Food and Drug Administration regulations. Baxter's trial was the first study to take advantage of the new rules, which were designed to facilitate research in emergency medicine that could not happen if doctors had to take the time to get consent.

But in addition to encouraging new discoveries, the regulatory change broke with a 50-year-old doctrine requiring informed consent in virtually all experiments on humans. The failure of the Baxter trial has led some ethicists to question the wisdom behind the rule change.

"People get involved in something to their detriment without any knowledge of it," said George Annas, a professor of health law at the Boston University School of Public Health. "We use people. What's the justification for that?"

First articulated at the Nuremberg trials as a way to prevent hideous experiments such as those performed by Nazi doctors during World War II, informed consent became the guiding principle of research on humans in

SEE CONSENT, PAGE 8

KEY TO FUTURE
DOCUMENTS (FORTHCOMING)
LATER

FYI From:

ANGIE HENDRICKSON
(WI.)

18A · MONDAY, APRIL 12, 1999 · USA TODAY

GULF WAR ILLNESS: The General Accounting Office and Rep. Jack Metcalf, R-Wash., are pointing to a controversial vaccine additive as a possible cause of Gulf War illnesses, the mystery sicknesses complained of by about one-sixth of those who served in the 1991 war.

Metcalf has asked the House Armed Services and Veterans' Affairs committees to investigate the possible use of an experimental substance called "squalene" in vaccinations designed to protect troops against biological warfare.

Armed with a GAO report critical of the Pentagon and with the results of some private scientific research, Metcalf wants the committees to push the Defense Department into doing its own tests of Gulf War veterans for evidence of squalene, which is a fatty substance found in minute quantities in the human liver. It has long been eyed by scientists as a possible addition to vaccines to make them work faster and longer. It is unlicensed and has yet to be approved by the Food and Drug Administration for human use.

Several studies have found injected squalene triggers arthritis and other immune system afflictions in rats and monkeys.

The Pentagon for years has steadfastly denied it used any squalene in troop vaccinations.

— John Hanchette, Gannett News Service

By Paul Leavitt with staff and wire reports

(continued from front flap)

No one knows the actual capabilities of biological weapons better than Dr. Alibek. Many of the scientists who worked with him have been lured away from low-paying Russian labs to rogue regimes and terrorist groups around the world. In our lifetime, we will most likely see a terrorist attack using biological weapons on an American city. *Biohazard* tells us—in chilling detail—what to expect and what we can do. Not since Arthur Koestler's *Darkness at Noon* has there been such a book—a report from inside the belly of the beast.

ABOUT THE AUTHORS

KEN ALIBEK was born in Kauchuk, Kazakhstan, in 1950. He graduated in 1975 from the military faculty of the Tomsk Medical Institute, where he majored in infectious diseases and epidemiology. He holds a Ph.D. in microbiology for research and development of plague and tularemia biological weapons and a doctorate of science in biotechnology for developing the technology to manufacture anthrax on an industrial scale. He joined Biopreparat in 1975 and was its first deputy chief from 1988 to 1992. Since his defection to the United States in 1992, he has briefed U.S. military intelligence on biological weapons. He is now working in biodefense.

STEPHEN HANDELMAN is a columnist at *Time*. He was the Moscow bureau chief of *The Toronto Star* in the late eighties and early nineties and is the author of *Comrade Criminal: Russia's New Mafiya*.

LOS ALAMOS, N.M.

Lab postpones release of biowarfare agent

Scientists have postponed indefinitely a planned Monday open-air release of bacteria that would have been used to test biowarfare detectors intended for battlefield use.

The planned tests at Los Alamos National Laboratory have raised questions about the lab's openness with the public as scientists expand their research into identifying and defending against biowarfare agents.

Homeowners in nearby White Rock complained to senior lab managers.

FPT

U.S.A. \$24.95
Canada \$37.95

THEY CLAIMED THEY WERE MAKING VACCINES. BUT WHAT WAS REALLY GOING ON IN THOSE LABS?

Imagine a hot zone in which Ebola is being spliced—using the latest techniques of genetic engineering—with smallpox, the most infectious disease known to man. Now imagine that cocktail is meant for you.

For fifty years, while the world stood in terror of a nuclear war, Russian scientists hidden in heavily guarded secret cities refined and stockpiled a new kind of weapon of mass destruction—an invisible weapon that would strike in silence and could not be traced. It would leave hundreds of thousands dead in its wake and would continue to spread devastation long after its release. The scientists were bioweaponeers, working to perfect the tools of a biological Armageddon. They called it their Manhattan Project. It was the deadliest and darkest secret of the cold war.

What you are about to read has never before been made public. Ken Alibek began his career as a doctor wanting to save lives and ended up running the Soviet biological weapons program—a secret military empire masquerading as a pharmaceutical company. At its peak, the program employed sixty thousand people at over one hundred facilities. Seven reserve mobilization plants were on permanent standby, ready to produce hundreds of tons of plague, anthrax, smallpox, and Venezuelan equine encephalitis, to name only a few of the toxic agents bred in Soviet labs. Almost every government ministry was implicated, including the Academy of Sciences and the KGB.

Biohazard is a terrifying, fast-paced account of tests and leaks, accidents and disasters in the labs, KGB threats and assassinations. The book is full of revelations—evidence of biowarfare programs in Cuba and India, actual deployments at Stalingrad and in Afghanistan, experiments with mood-altering agents, a contingency plan to attack major American cities, and the true story behind the mysterious anthrax outbreak in Sverdlovsk. But beyond these is a twisted world of lies and mirrors, and the riveting parable of the greatest perversion of science in history.

(continued on back flap)

Subj: Equal Time
Date: 97-08-30 10:08:00 EDT
From: dgpowell@ix.netcom.com (David Powel)
Sender: sender-hemophilia-support@web-depot.com
Reply-to: Hemophilia-Support@web-depot.com, dgpowell@ix.netcom.com (David Powel)
To: Hemophilia-Support@web-depot.com

Friday on NBC Nightly News:

"Which pain reliever do you use when your head aches or your back is sore? Aspirin is a miracle drug that's been around for a hundred years, but when should you take it?

Don't miss our report."

NBC News

The Power Of Bayer, and so Much More...

Major broadcast story on Bayer last night and no mention of the I.G. Farben, Zyklon-B in WWII concentration camps, nor thousands of hemophiliacs dead from AIDS and Hepatitis from Bayer products 50 years later?

Bayer seems to be gearing up for the 100th anniversary of aspirin, a national in-depth story by NBC is just one of many media segments so far with the Bayer cross displayed.

The historical record: Bayer Corporation based in Leverkusen, Germany, was stripped of all marketing rights to the Bayer aspirin name in America after World War I for war reparations.

Later, during World War II, the Zyklon-B problem and concentration camp medical experimentation on inmates led to a the Nuremberg based informed consent laws common today.

In 1963, Fritz ter Meer, convicted of mass murder and human slavery at Nuremberg, was chairman of the Bayer Corporation, evolved from the I.G. Farben ashes of WWII (along with BASF and Hoescht [Centeon]).

Not until the early 1990's did Bayer in Leverkusen regain the right to use the Bayer name in America for aspirin with the acquisition of Sterling Drug.

The loss of the Bayer name in America after world war one is always a sore spot with the management in Leverkusen.

Equal time for 6 million Jews and ten thousand Hemophiliacs.

David

Subj: Bad Boys
Date: 97-04-07 04:55:44 EDT
From: dgpowell@ix.netcom.com (David Powell)
Sender: sender-hemophilia-support@Web-Depot.COM
Reply-to: Hemophilia-Support@Web-Depot.COM
To: Hemophilia-Support@Web-Depot.COM

"This letter you posted is amazing. Obviously they knew there was a problem but didn't recall the stuff. Do you know the approximate date when the heat treated factor came on the market? How long did it take before they purified out the HIV tainted product?"

In the late 1970's BehringWerke in Germany had a pasteurization solution.

We have Cutter Biologicals doing early heat treat experiments in the early 1970's with chimpanzees.

In 1983, Baxter was granted a heat treatment license from the FDA, in February 1984 Cutter was granted a FDA license for Factor VIII heat treatment.

Duncan Barr is creaming every defendant on the planet about this time.

And Michael Stough is still in business with Gagnard and Davis in the plasma trade.

Mr. Reilly, President of ABRA and Chief Scum speaks every week with lie after lie from ABRA.

Professional Medical Associations know ABRA is a joke, a stupid representation of what might be truth. Mr. Reilly, do you really think that anyone can take you seriously after so many lies on behalf of ABRA? That anyone believes that you represent the medical profession?

That ABRA represents the medical profession? Give me a break, ABRA.

Good Luck!

And call Lou Aledort to help you, the "Hospital Practice" article in 1982 always seemed to help in prior cases in the 1980's.

David

. Postings: Hemophilia-Support@Web-Depot.COM
. Anonymous Postings: Anonymous-Hemophilia-Support@Web-Depot.COM
. Subscription Requests: Hemophilia-Support-Approval@Web-Depot.COM
. Questions: Owner-Hemophilia-Support@Web-Depot.COM
. World Wide Web: <http://www.web-depot.com/hemophilia>
. Hemophilia-Support is a free service provided by the Web-Depot, Inc.

million was spent for research and development. Bayer Corporation, with headquarters in Pittsburgh, is a member of the worldwide Bayer Group, a \$32.4 billion chemical and pharmaceutical company based in Leverkusen, Germany.

For U.S. investors, bearer's shares of Bayer Group can be purchased directly on 15 major stock exchanges such as Frankfurt, London, Paris, and Tokyo. In the United States, Bayer equity is available in the form of American Depositary Receipts (ADRs). An ADR is equal to one bearer share.

SOURCE Bayer Corporation

CONTACT: Bayer Corporation Media Line, 412-777-5666

****Paul Vess Rockwell, North Carolina USA **HEMOfact Mailing List**** HEMOfact is a private list dedicated to providing hemophilia related NEWS and INFO. Subscriptions send email w/request to: veracity@interpath.com Hemophiliacure LINKS&INFO: http://www.geocities.com/wallstreet/1450/*****Original proponent for the alt.support.hemophilia newsgroup*****

.....

. Please visit SinglesCoupled.COM our new online personals site .

. Postings: Hemophilia-Support@Web-Depot.COM .

. Anonymous Postings: Anonymous-Hemophilia-Support@Web-Depot.COM .

. Subscription Requests: Hemophilia-Support-Approval@Web-Depot.COM .

. Questions: Owner-Hemophilia-Support@Web-Depot.COM .

. World Wide Web: <http://www.web-depot.com/hemophilia> .

.....

----- Headers -----

From sender-hemophilia-support@merlin.web-depot.com Fri Apr 4 03:03:05 1997
Return-Path: <sender-hemophilia-support@merlin.web-depot.com>
Received: from mrin15.mail.aol.com (mrin15.mail.aol.com [152.163.116.37])
by emin14.mail.aol.com (8.8.5/8.8.5/AOL-2.0.0)
with ESMTP id DAA12191;
Fri, 4 Apr 1997 03:02:57 -0500 (EST)
Received: from merlin.web-depot.com (merlin.web-depot.com [207.92.77.2])
by mrin15.mail.aol.com (8.8.5/8.8.5/AOL-2.0.0)
with ESMTP id DAA24073;
Fri, 4 Apr 1997 03:02:53 -0500 (EST)
Received: (from daemon@localhost) by merlin.web-depot.com (8.8.5/8.7.3) id CAA07028 for hemophilia-support-outgoing; Fri, 4 Apr 1997 02:26:04 -0500 (EST)
Date: Fri, 4 Apr 1997 01:31:21 -0600 (CST)
Message-Id: <199704040731.BAA13793@dfw-ix9.ix.netcom.com>
From: dgpowell@ix.netcom.com (David Powell)
Subject: Helge Reports on Bayer Corporation
To: Hemophilia-Support@web-depot.com
Sender: sender-hemophilia-support@web-depot.com
Errors-To: sender-hemophilia-support@web-depot.com

aim to be one of the top three companies in the \$2 billion U.S. animal health business. The investments will also enable the company to: have manufacturing capacity to serve the growing needs of Bayer affiliates in the NAFTA region and help the Bayer Group realize its strategy of globalizing the manufacture of animal health products.

Committed to R&D

"In research and development, our \$4.1 billion investment represents Bayer Corporation's steadily increasing responsibilities for the worldwide Bayer Group," said Wehmeier. "Eighty percent of our R&D dollars are invested in the life sciences businesses."

The investments include:

- Billions in pharmaceutical research, much of it at the Bayer Research Center in West Haven, Conn., one of the three anchors in the Bayer Group's global pharmaceutical research triangle. At the center, hundreds of scientists are engaged in research into treatments for dementia, cancer, rheumatic diseases and metabolic disorders. Products in the Bayer pipeline include promising new drugs for lowering cholesterol, alleviating the suffering of Alzheimer's patients, treating AIDS patients, treating septic shock and meeting other critical patient needs.

- Hundreds of millions for investments in biotechnology, a cornerstone for the Bayer Group's strategy for growth in pharmaceuticals. One notable result is the company's construction of a new biotechnology production facility in Berkeley. The investments also support research underway at Bayer and with biotechnology partners to provide advanced treatments for hemophilia, asthma, cancer and other health care challenges.

- Our R&D funding will also ensure that the chemical portion of the business continues to stay on the cutting edge, offering our customers the latest materials and high-performance products.

"This investment and our plans for the future make it a very exciting time for Bayer," Wehmeier said, "for our employees and for our plant communities."

"In summary," Wehmeier added:

- We are growing to grasp market opportunities.
- We are developing new, innovative products.
- We have received expanded responsibilities within the Bayer Group and are playing a key role in worldwide operations.
- We are improving our return on investment and overall financial statement.
- We are involved in our communities with award-winning programs like "Making Science Make Sense," which seeks to help schools increase science literacy across the U.S.
- We have a strong environmental protection program and a safety record that has improved for nine consecutive years."

Bayer Corporation is a research-based company with major businesses in health care and life sciences, chemicals and imaging technologies. The company had 1996 sales of \$9 billion with operating income of \$736 million, excluding one-time charges, and employs 24,000 people. Capital expenditures for 1996 totaled \$632 million and \$621

"Beyond internal operations, the United States makes for an attractive investment largely because it is the largest single market in the world and the center of the NAFTA region," said Wehmeier. "Indeed, in total, Bayer has spent over \$2 billion on acquisitions in the United States during the past two-and-a-half years."

According to Wehmeier, the United States offers the Bayer Group close proximity to many of its global customers and competitors and has a chemical industry infrastructure that allows unsurpassed manufacturing efficiencies. The country also is a logical site for leading-edge research, with its expertise in biotechnology, diagnostics, medicine and other areas. A skilled workforce, stable economy and entrepreneurial attitudes contribute to Bayer's favorable opinion of the U.S. market.

Capital Investments

When complete, Bayer's \$4.6 billion in capital expenditures will include:

- A \$1.2 billion investment in Bayer's chemical manufacturing complex in Baytown, Texas, to expand production capacities for polyurethane raw materials, polycarbonate resin and other fundamental building-block chemicals.

\$280 million alone is being invested primarily to help Bayer Corporation meet growing domestic and foreign demand for polyurethane systems in automotive, appliance, construction and other industries. In addition, Bayer will invest approximately \$500 million for infrastructure and other raw materials for its isocyanates manufacturing lines, including a chlor alkali facility in Baytown. With this investment, the company will operate Bayer's largest facility in the world for producing diphenyl methylene diisocyanate (MDI), an important polyurethane raw material.

- Bayer is investing more than \$850 million in pharmaceutical operations, including major expansions in Berkeley, Calif., West Haven, Conn., and Clayton, N.C.

Berkeley is the headquarters location for the Bayer Group's worldwide biotechnology business, which includes a \$100 million state-of-the-art biotechnology facility. According to Wehmeier, the site is pivotal to the Bayer Group's strategy for growth in pharmaceuticals. Kogenate, Bayer's first biotechnology drug for treating hemophilia, is produced at the Berkeley site.

In Clayton, Bayer is enlarging and upgrading its plasma fractionation facility to help meet strong global demand for plasma products that treat conditions such as immune system deficiencies, blood clots and genetic emphysema.

In West Haven, the company has consolidated and expanded its U.S. pharmaceutical headquarters. The site also is headquarters for the North American region of Bayer's worldwide pharmaceutical business.

- Capital expenditures totaling more than \$330 million are committed for the Agriculture Division. They include an expansion and upgrade of animal health production operations in Shawnee, Kan., a crop herbicide production facility in 1997 and Bayer's recent acquisition of Pharmacia & Upjohn's biological business.

These actions support several goals for the company, including its

Subj: Helge Reports on Bayer Corporation
Date: 97-04-04 04:59:48 EST
From: dgpowell@ix.netcom.com (David Powell)
Sender: sender-hemophilia-support@web-depot.com
Reply-to: Hemophilia-Support@web-depot.com
To: Hemophilia-Support@web-depot.com

— Begin Forwarded Message

Subject: Bayer Announces \$9.0 Billion U.S. Investment Strategy
To: HEMOFACT@MAELSTROM.STJOHNS.EDU

Bayer Announces \$9.0 Billion U.S. Investment Strategy; Major Capital Expansion For Chemicals, Life Sciences; U.S. Corporation Posts Robust Sales Increase

PITTSBURGH, April 2 /PRNewswire/ – In a move that will strengthen its position in the U.S. market and allow it to shoulder growing responsibilities for the worldwide Bayer Group, Bayer Corporation today announced that Bayer is investing approximately \$9.0 billion in the U.S. operations from 1995 through the year 2000.

The investments include \$4.6 billion in capital expenditures and \$4.1 billion in research and development, according to Helge H. Wehmeier, President and CEO of Bayer Corporation. Wehmeier made his remarks during a news conference held from Bayer Corporation's headquarters in Pittsburgh.

"Our U.S. operations are on the move and \$8.7 billion in investments provide us with lots of fuel to accomplish our goals," said Wehmeier. "The Bayer Group chose the United States for this significant investment activity because we have a proven track record of success and because the United States offers important business and market advantages."

Bayer Corporation is the largest subsidiary of the Bayer Group, one of the world's leading pharmaceutical and chemicals companies. Last year's \$9 billion in U.S. net sales, an increase of 14 percent over 1995, represented a quarter of the worldwide Bayer Group's total 1996 sales of \$32.4 billion. The U.S. company's 1996 exports totaled \$1.5 billion and are projected to rise to \$2 billion or more by the end of the year 2000. Bayer Corporation has 24,000 employees.

Logical Investment Choice

Investing in the U.S. operations was a logical choice for Bayer, according to Wehmeier. Bayer Corporation's net sales have increased 50 percent from their 1992 total of \$6.1 billion. This significant jump is the result of internal growth and several major acquisitions.

Productivity in the United States, as measured in sales per employee, also improved, up 50 percent in just five years. And, the company currently is involved in a number of internal initiatives to further optimize cost efficiencies and realize synergies in company-wide business processes, purchasing and asset management, as well as a strong environmental protection program and a safety record with nine consecutive years of improvement.

Food and Drug Administration Still Has Problems Ensuring Safe Blood

Feedback	Index	Search	Customize	Individual
Main	▲ Up	◀ Previous Story	Next Story ▶	Calendar

Date: Monday, June 9, 1997

Source: The Philadelphia Inquirer

The Philadelphia Inquirer via Knight-Ridder/Tribune via Individual Inc. : By Donna Shaw and Josh Goldstein
Knight-Ridder/Tribune Business News

WASHINGTON--Jun. 6--Two years after a government commission blamed the Food and Drug Administration for "a failure of leadership" that allowed HIV-tainted blood products to kill thousands of Americans, the agency continues to stumble.

Dangerous blood products take a month to recall, even after they are identified. Patients aren't notified when they have used contaminated medicines. If physicians call the FDA's emergency hotline on weekends or holidays, they get clerks, not medical experts.

Those deficiencies and more were the subject of testimony and government reports released Thursday by a congressional subcommittee that is investigating the safety of the nation's blood supply.

"The number and scope of recent blood-product recalls provides further evidence of a fraying regulatory safety net," said U.S. Rep. Christopher Shays (R., Conn.), chairman of the Subcommittee on Human Resources of the House Committee on Government Reform and Oversight.

In a series of reports, the General Accounting Office, the Department of Health and Human Services, and the FDA's Office of Special Investigations cited a long list of FDA lapses. The agency acknowledged most of them but said it was making "substantial progress" toward reforms.

In particular, the FDA has transferred responsibility for inspections of plasma-products manufacturers to a division whose primary function is such reviews, said Michael A. Friedman, the agency's lead deputy commissioner. Previously, that responsibility had been handled by scientists and administrators at the FDA's Center for Biologics Evaluation and Research.

"We are absolutely committed to these efforts and we will not rest until we are assured that the blood supply is as safe as is possible," Friedman said.

Among the problems identified by the investigators:

-- In an incident last summer in Kansas, a hospital patient went into septic shock and nearly died after receiving Albuminar, a plasma product. Tests showed that the product was contaminated with the same bacteria that had sickened the patient, and the hospital immediately reported the incident to an FDA hotline. But the call was handled by data-entry personnel; it was a month before the urgent nature of the incident was recognized and a product recall was ordered. By then, 33 possible cases of adverse reactions to Albuminar had been reported.

A subsequent investigation determined that not once in 50 years had the government inspected the

Subj: Subcommittee hearing article-Phily Inquirer
Date: 97-06-07 05:28:00 EDT
From: rebis@ime.net (Terry)
Sender: sender-hemophilia-support@web-depot.com
Reply-to: Hemophilia-Support@web-depot.com
To: Hemophilia-Support@web-depot.com (Hemophilia-Support@Web-Depot.Com)

– [From: Terry * EMC.Ver #2.5.02] –

FDA cited over safety of blood products

There have been delays in recalls and a lack of information for patients.
The

agency said it was making progress.

By Donna Shaw
and Josh Goldstein
INQUIRER STAFF WRITERS

WASHINGTON – Two years after a government commission blamed the Food and Drug Administration for "a failure of leadership" that allowed HIV-tainted blood products to kill thousands of Americans, the agency continues to stumble.

Dangerous blood products take a month to recall, even after they are identified. Patients aren't notified when they have used contaminated medicines. If physicians call the FDA's emergency hotline on weekends or holidays, they get clerks, not medical experts.

Those deficiencies and more were the subject of testimony and government reports released yesterday by a congressional subcommittee that is investigating the safety of the nation's blood supply.

"The number and scope of recent blood-product recalls provides further evidence of a fraying regulatory safety net," said U.S. Rep. Christopher Shays (R., Conn.), chairman of the Subcommittee on Human Resources of the House Committee on Government Reform and Oversight.

In a series of reports, the General Accounting Office, the Department of Health and Human Services, and the FDA's Office of Special Investigations cited a long list of FDA lapses. The agency acknowledged most of them but said it was making "substantial progress" toward reforms.

In particular, the FDA has transferred responsibility for inspections of plasma-products manufacturers to a division whose primary function is such reviews, said Michael A. Friedman, the agency's lead deputy commissioner. Previously, that responsibility had been handled by scientists and administrators at the FDA's Center for Biologics Evaluation and Research.

"We are absolutely committed to these efforts and we will not rest until we are assured that the blood supply is as safe as is possible," Friedman said

----- Headers -----

From sender-hemophilia-support@merlin.web-depot.com Fri Jun 6 19:13:15 1997
Return-Path: <sender-hemophilia-support@merlin.web-depot.com>
Received: from merlin.web-depot.com (merlin.web-depot.com [207.92.77.2])

HOW DO I GET THESE?

Recent Testimony from the U.S. Food and Drug Administration

- Testimony of Dr. Thomas Shope, June 26, 1997
Acting Director, Division of Electronics and Computer Science before the subcommittee on Oversight and Investigations, Committee on Veteran's Affairs, U.S. House of Representative on "Year 2000" date issue as it related to medical devices.
- Testimony of Dr. Michael A. Friedman, June 5, 1997
Lead Deputy Commissioner of Food and Drug Administration before the Subcommittee on Human Resources and Intergovernmental relations U.S. House of Representatives on FDA's role in regulating and protecting the nation's blood supply.
- Testimony of Dr. Michael A. Friedman, April 30, 1997
Lead Deputy Commissioner, Food and Drug Administration before the Subcommittee on Health and The Environment on Reauthorization of the FDA's Medical Device Program.
- Testimony of Dr. Michael A. Friedman, April 23, 1997
Food and Drug Administration before the Subcommittee on Health and The Environment on Reauthorization of the Prescription Drug User Fee Act of 1992.
- Testimony of Dr. Michael A. Friedman, March 19, 1997
Deputy Commissioner for Operations, Food and Drug Administration before the Committee on Labor and Human Resources on FDA's Accomplishments and Proposals.
- Testimony of William B. Schultz, February 6, 1997
Deputy Commissioner for Policy, Food and Drug Administration, before the Subcommittee on Oversight and Investigations on FDA's regulation of products that can be used in the home and in other nonprofessional settings (over-the-counter (OTC)) to test for drugs of abuse.
- Testimony of Dr. Bruce Burlington, September 26, 1996
Director, Center for Devices and Radiological Health, Food and Drug Administration, before the Subcommittee on Oversight and Investigations on medical diagnostic test.
- Testimony of Mary Pendergast, September 17, 1996
Deputy Commissioner and Senior Advisor to the Commissioner, Food and Drug Administration before the Subcommittee on Technology, Committee on Science - Technological developments in genetic testing.
- Testimony of Sharon S. Holston, May 23, 1996
Deputy Commissioner for External Affairs, Food and Drug Administration before the Committee on Transportation and Infrastructure, House of Representatives.
- Testimony of Michael Friedman, M.D., May 22, 1996
Deputy Commissioner for Operations, Food and Drug Administration before the Subcommittee on Livestock, Dairy and Poultry, Committee on Agriculture.
- Testimony of David A. Kessler, M.D., May 2, 1996
Commissioner of Food and Drug, Food and Drug Administration, before the Committee on Appropriations.

- Testimony of Michael Friedman, M.D., May 10, 1996
Deputy Commissioner for Operations, Food and Drug Administration, Foodborne Illnesses, Subcommittee on Human Resources and Intergovernmental Relations House Committee on Government Reform and Oversight
- Testimony of David A. Kessler, M.D., March 12, 1996
Commissioner of Food and Drug, Food and Drug Administration, before the Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, Committee on Appropriations, U.S. House of Representatives.
- Testimony of William B. Schultz, February 22, 1996
Deputy Commissioner for Policy, Food and Drug Administration, before the Committee on Labor and Human Resources, United States Senate.
- Testimony of David A. Kessler, M.D., February 21, 1996
Commissioner of Food and Drug, Food and Drug Administration, before the Committee on Labor and Human Resources, United States Senate.

FIT AT FORTY • FIFTY • SIXTY and BEYOND

The in-depth health and nutrition analysis

REPORT

By: Dr. Ted Broer

Volume 1 Number 2

ASPARTAME: A CHRONICLE OF CRIME

- How did a laboratory accident make it into your food supply?
- Methanol is 10% of Aspartames molecular structure!
- Every single monkey in one study developed seizures!
- From brain Cancer to Depression why were we not told the truth?

Last year the Food and Drug Administration (FDA) passed the Truth in Food Labeling Act which mandated that food manufacturers disclose a complete list of their products' ingredients, and that titles on food labels must honestly represent the contents within the package. This means that a Low Fat product must, in fact, be low in fat and that "light" means that the product is lighter in calories, not just in the weight of the package. Thus, I am astounded that a product marketed as an artificial sweetener can carry the name NutraSweet, when 1) it is not nutritive by definition, and 2) it is shown to be a hazardous chemical causing severe side effects including headaches, seizures and even birth defects in laboratory animals. One would think that our government would protect us from products that are known to harm us, but in the case of aspartame, which is marketed under the name of NutraSweet, they have not. If the public fully understood the irregularities in the research and development of aspartame and The Food and Drug Administration's (FDA) approval process of this chemical, the cries of conspiracy would be heard far and wide. The path that took this chemical from the laboratory to your kitchen table is one wrought with deception and blatant conflicts of interest, not to mention what could be considered a conspiracy to market a product to Americans which has been proven to be harmful.

Many are not aware, but NutraSweet was not the product of researchers seeking a healthy sugar substitute to benefit society. It was actually an accidental discovery by James Schlatter, Ph. D. who was conducting research for the G.D. Searle Company on a drug designed to treat ulcers. In December, 1965, while Dr. Schlatter worked in the laboratory on his prospective anti-ulcer medication, he mixed a substance in a container, called aspartame, with methanol (wood alcohol) when some of the substance accidentally spilled to the outside of the flask. When Dr. Schlatter picked up the flask, the substance rubbed onto his fingers. A few moments later, when Dr. Schlatter licked his finger to pick up a piece of paper, he reportedly noticed a very strong sweet taste. Not knowing exactly what had happened or where the sweetness came from, Dr. Schlatter soon discovered it

had come from the contents of his experiment.¹ From this laboratory accident a legacy of deception has been forged against the American people which can only be considered a crime against humanity. You will find in the pages that follow a chronology of the FDA approval process of aspartame, as well as numerous documented irregularities, deceptions and conflicts of interest. You will also find a full discussion of the deleterious effects of aspartame on the human body which will lead you to question whether the Federal Drug Administration (FDA) is really looking out for the health and well being of your family or whether it is merely a puppet of big business.

Under regular FDA guidelines, when a new chemical designed for human consumption is invented in the United States it normally takes a long time to get from the laboratory to the kitchen table. Under most circumstances these chemicals are tested extensively on laboratory animals and then tested on human subjects before they are ever allowed to be manufactured and sold for human use. If the chemicals are found to be reasonably safe ("reasonably safe" meaning that they are found to cause cancer in less than three [3] in one million people) it is allowed to be marketed for human consumption. Chemicals which are not shown to be safe for human use are not supposed to earn FDA approval. These products must go back to the laboratory for further research and development which is a very costly venture for the manufacturer. If the chemical is found to be hazardous to one's health after it has been authorized for marketing, the chemicals are supposed to be pulled from the market, as was the case for Red Dye #19. If the product is not recalled, a warning label must be attached as is the case of saccharine. NutraSweet, touted as the most tested product in the world, has managed to beat this system. Unknown to the general public, the company which manufactures aspartame has been accused of providing falsified test results to the FDA and even unethical deal making with prosecutors from the United States Attorney General's office. All the while, reports of adverse patient reactions including headaches, memory loss and seizures, and even confirmed death continue to mount while these reports are being kept from the general public.

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. letter	re: Personal finances (1 page)	06/30/1998	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office

OA/Box Number: 21067

FOLDER TITLE:

Angie Hendrickson [1]

2018-0764-F
jm2213

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

ANY
CONNECTION-
TOO MANY
"CONFIDENCES"

TO OVERLOOK ANYTHING...

COMMUNITY NEWS

JULY 29, 1999

WAUPACA COUNTY POST

Sheriffs least compliant with open records law

Statewide audit finds officials refusing to disclose public records

More than half of Wisconsin's 72 sheriffs' departments failed to comply with provisions of the state's Open Records Law in a recent audit directed by the Wisconsin Freedom of Information Council.

A total of 13 sheriffs' offices refused outright to release lists of people they had arrested in the previous week. Another 30 released the information only after making the requesters comply with requirements not authorized by the Open Records Law.

Sheriffs' departments were just one of five governmental areas tested mostly during April and May in the first-ever audit of the condition of governmental openness in Wisconsin.

The Freedom of Information Council, a statewide organization that advocates for open government, organized volunteers in each of the 72 counties. They, in turn, sought access to routine public records from sheriffs and county clerks and from randomly-selected school districts and municipal offices in each of the counties.

The audit revealed that administration of the open records law varies greatly from county to county and often clerks and others charged with handling requests find the law confusing. The sheriffs were by far the least cooperative in complying with requests for arrest logs.

Some insisted they had no idea what the requester was asking for, others said the list was no one's business in the first place. Some made the requester wait several days for the information.

"If you were arrested, you wouldn't want your name released, would you?" asked one deputy sheriff.

A 1979 landmark Wisconsin Su-

preme Court decision involving the *Milwaukee Journal* and then Milwaukee Police Chief Harold Breier, ruled that arrest records are public information in Wisconsin.

"The court declared that the power to arrest is among the most awesome powers of the state," said James Friedman, a First Amendment lawyer with the Madison-based firm of La Follette and Sinykin. "The justices said that without public oversight of this awesome power, we run the risk of creating a police state."

For the most part, custodians in the other four areas tested by the audit, received high marks. School district clerks, who were asked for copies of the most recent school board meeting minutes, were the most compliant. All but one produced the minutes when asked.

However, school clerks were somewhat less willing to release the salaries paid to their basketball and football coaches.

Five of the 72 districts tested refused to reveal the taxpayer-paid salaries, a violation of state law, and seven more demanded the requester provide personal information that the open records law expressly says cannot be required as a condition to releasing the record.

Only three of the 72 county clerks refused to turn over records of the per diem payments to county supervisors while nine town, village or city clerks turned down requests to see how much their respective governmental units had paid for legal services during the past year.

Attorney General James Doyle, who has conducted periodic open records seminars to educate public officials on the law, said that with the exception of the sheriffs' departments, he views the overall results as "generally good."

"The audit confirms our sense that there needs to be ongoing education for public officials on the importance of open records and what the law re-

quires of them," he said. "Once you train a group, another group of public officials comes along. We have to keep at it."

Doyle attributed the lack of compliance among the sheriffs' offices to a confusion that has resulted from recent court decisions.

"There is no question that arrest logs are public records," the attorney general added. "But a perception has grown that somehow law enforcement records can be treated differently because of decisions that have been definite setbacks for openness."

Doyle suggested that the Wisconsin Legislature ought to take a "good look" at the confusion that has resulted and seek a remedy.

Milton Marquardt, the president of Wisconsin's Sheriffs and Deputy Sheriffs Association, said he was "concerned" about the results.

"There's no question that we all need to abide by the open records law," he said.

But, like Doyle, he blamed confusion on the part of sheriffs and their staffs because of recent court decisions and advice that county corporation counsels may give in different counties.

"No one wants to break the law," Marquardt, the chief deputy in Shawano County, said. "But sometimes it depends on who is asked for the information. It may be a clerk versus the sheriff and not everyone has the same knowledge."

Wisconsin's Open Records Law, passed by the Legislature in 1981, was designed to give Wisconsin citizens easy access to information about their local and state governments. The law requires each "public body" to appoint a records custodian to answer requests for information.

Custodians who violate the open records law can be prosecuted by the districts attorney or the attorney general and fined up to \$1,000 if they are found to have willfully violated the law.

The volunteers in the 72 counties were primarily members of Wisconsin media organizations, but sought the information as "ordinary" citizens in order to test how the general public would be treated.

In all but a few instances, most of the volunteer auditors were unknown to the public officials. Under the law, a custodian cannot require the seeker of information to identify him or herself as a condition to obtain the records.

HOW WILL YOU BE IDENTIFIED?

YOUR CHOICE

As a patient, you have a right to privacy. You decide who knows about your medical care. You choose to share information from your doctor's visit with family and friends. You determine the course of your care.

Not anymore.

Imagine being labeled by your medical condition. Your privacy is invaded. Your relationship with your doctor is threatened. Perhaps your health insurance becomes out-of-reach.

PRIVATE MEDICAL INFORMATION MADE PUBLIC

A new Wisconsin law requires your doctor to supply the state government with information relating to your doctor visits. The reports, based on more than 13,000 diagnostic codes, are extremely detailed.

You should be concerned.

This law allows your personal information to be released to the general public and employers. Although your name will not be attached, certain identifiable factors, such as your age, gender and zip code may distinguish you.

And, you have no choice when your private medical information is sent to the state. Nor does your doctor. In fact, patients do not have to be told that their information is being forwarded.

REQUIRE WRITTEN CONSENT

The doctors of the State Medical Society of Wisconsin (SMS) believe that patients should decide if their personal medical information should be released to the state. The SMS is supporting legislation that would require your written consent for the release of your medical information. It's a choice all patients should be given. It preserves your relationship with your doctor.

CONTACT YOUR LEGISLATOR

The state legislature needs to hear from patients. Call your elected officials and ask them to support patient written consent for the release of private medical data to the state. Ensure your right to privacy.

Call your legislator at 800.362.9472 today!

FOR MORE
INFORMATION
CONTACT:

State Medical Society of Wisconsin
330 East Lakeside St.
P.O. Box 1109
Madison, WI 53701
800.362.9080, 608.257.6781
www.wismed.com

FCC cell phone proposal spurs privacy alarms

By Frank James
WASHINGTON BUREAU

WASHINGTON—Wireless phones clearly have brought a dramatic freedom to modern life. But these omnipresent symbols of the communications revolution may be turned into tracking devices to locate their owners, in the process raising a vivid challenge to privacy.

In a little-noticed effort, the Federal Communications Commission wants to make mobile phones disclose their locations when used to place emergency 911 calls, just like their wired counterparts.

That would open the door to potentially widespread misuse by government and private industry, though the technology also has useful applications in helping find people who are lost or need assistance.

In August, there were two other developments with privacy implications: The FCC gave law-enforcement authorities broader help in wiretapping new, digital phone networks, while a federal appeals court in Denver struck down restrictions on what personal information telephone companies can disclose concerning customers' billing records.

Those decisions help explain the concerns prompted by the FCC's "enhanced 911" or "E911" effort. The agency has given mobile phone service providers a deadline of Oct. 1, 2001, after which they must be able to give emergency officials a wireless phone

SEE PRIVACY, PAGE 8

COURTS BACK BAD BLOOD VICTIMS

TOKYO: (AP) -- In a major step toward compensating Japanese infected with the AIDS virus by tainted blood, two courts urged the government and drug companies Friday to pay \$450,000 to each of more than 2,000 victims.

In response to a suit by victims, the courts proposed the government and drug companies be held accountable for allowing the blood products to be distributed despite evidence they contained HIV, the virus that causes AIDS.

About one-third of the original group of 219 plaintiffs have died since first bringing their action six years ago. They originally had asked for \$1.2 million each. The courts said all those infected should be compensated.

The proposal by the Tokyo and Osaka district courts essentially orders the sides into an out-of-court settlement. The decision is not legally binding, but such orders are usually followed in Japan.

More than 2,000 Japanese, most of them hemophiliacs, were infected with the virus from American-made blood products between 1985, when U.S. medical authorities warned of possible infections, and 1987, when Japan took action.

Critics have said the government dragged its feet until Japanese companies developed the technology to treat the blood rather than use American methods.

AIDS Lawsuit

USA Today (10/06/95) P. 3A; Leavitt, Paul; Rivera, Patricia. V.; Goodwin, M. David; et. al.

Collegeville, Pa.-based Armour Pharmaceutical Co. has agreed to an out-of-court settlement with three of six Canadian hemophiliacs who claim they were infected with HIV from tainted blood products, according to the Philadelphia Inquirer. Each of the three plaintiffs will receive \$1.55 million. Documents presented as evidence at a government hearing in Toronto reveal that Armour continued to sell its blood-clotting product Factorate until 1987 even though it knew 10 years ago that its heat-treating process did not destroy HIV.

Related stories: Wall Street Journal (10/06) P. B7; Washington Post (10/06) P. A2; New York Times (10/06) P. A17.

SEP LOGS - 04-03-77

THE INC. COLUMN



Ellen Warren & Terry Armour

Rosemont mayor reels over visit by white separatist

Rosemont Mayor and political powerhouse **Don Stephens** has spent a career trying to build his suburb near O'Hare into a family-friendly entertainment and convention mecca. So he was surprised and angered to learn late this week that the village he has so fervently nurtured is hosting a convention featuring renowned white separatist **Randy Weaver**. Weaver is scheduled to speak at the Rosemont Convention Center Friday, Saturday and Sunday—all three days—at a gathering billed as the "Y2K

government groups. He is particularly in demand now that the government role in the deaths of the Branch Davidians at Waco is again in question.

Rosemont lawyers told Stephens that free speech guarantees of the 1st Amendment mean that the mayor couldn't cancel the convention (his first choice) or ban Weaver from speaking (his second).

Stephens' Jewish friends pointed out that the timing of the three-day Weaver appearance was particularly hurtful because it coincides with Rosh Hashanah, the Jewish New Year that begins at sundown Friday.

All the mayor could do was to order increased security at the convention center—and make it clear that the convention organizers must foot the bill.

tic
in
ed
ntil
ad,

c

Shrager, McDaid, Loftus, Flum & Spivey

BY: Wayne R. Spivey, Esquire/Daniel S. Weinstock, Esquire

IDENTIFICATION NUMBER: 31017/72940

32ND FLOOR

TWO COMMERCE SQUARE

2001 MARKET STREET

PHILADELPHIA, PENNSYLVANIA 19103

(215) 568- 7771

THAD W. JELINSKE, Guardian ad Litem
for BRANDON THOMAS LAPINSKI, a minor
and ANGELA HENDRICKSON, individually and
in her own right,

Plaintiffs

v.

ARMOUR PHARMACEUTICAL COMPANY,
et al.,

Defendants.

COURT OF COMMON PLEAS
PHILADELPHIA COUNTY

APRIL TERM, 1996

NO. 3590

ORDER

AND now, this ____ day of _____, 1999, upon consideration of the Petition for Leave to Settle or Compromise Minor's Action of Thad W. Jelinske, Esquire, as Guardian ad Litem for Brandon Thomas Lapinski, a minor, and by attorneys, Shrager, McDaid, Loftus, Flum & Spivey, it is hereby ORDERED and DECREED that petitioners are authorized to enter into such settlement in the amount of \$1,200,000.00.